Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
38
CHRS Quote, Financials, Valuation and Earnings
Last price:
$1.34
Seasonality move
:
0.05%
Day range:
$1.27 - $1.34
52-week range:
$0.71 - $1.89
Dividend yield:
0%
P/E ratio:
1.06x
P/S ratio:
1.86x
P/B ratio:
1.85x
Volume:
715.9K
Avg. volume:
939K
1-year change:
-10.07%
Market cap:
$162M
Revenue:
$267M
EPS (TTM):
-$1.59
Analysts' Opinion
-
Consensus RatingCoherus Oncology, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.67, Coherus Oncology, Inc. has an estimated upside of 322.89% from its current price of $1.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.34.
Fair Value
-
According to the consensus of 4 analysts, Coherus Oncology, Inc. has 322.89% upside to fair value with a price target of $5.67 per share.
CHRS vs. S&P 500
-
Over the past 5 trading days, Coherus Oncology, Inc. has underperformed the S&P 500 by -1.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Coherus Oncology, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Coherus Oncology, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Coherus Oncology, Inc. reported revenues of $11.6M.
Earnings Growth
-
Coherus Oncology, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Coherus Oncology, Inc. reported earnings per share of -$0.30.
Enterprise value:
24.6M
EV / Invested capital:
0.17x
Price / LTM sales:
1.86x
EV / EBIT:
4.21x
EV / Revenue:
0.29x
PEG ratio (5yr expected):
-0.90x
EV / Free cash flow:
-0.27x
Price / Operating cash flow:
189.35x
Enterprise value / EBITDA:
3.85x
Gross Profit (TTM):
$35.9M
Return On Assets:
-40.99%
Net Income Margin (TTM):
-224.34%
Return On Equity:
--
Return On Invested Capital:
-115.69%
Operating Margin:
-364.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $211.1M | $110.2M | $83.6M | $6.1M | $11.6M | |
| Gross Profit | $117.9M | $14.3M | $35.9M | $1.8M | $6.9M | |
| Operating Income | -$180.9M | -$215.8M | -$168.7M | -$46.9M | -$42.2M | |
| EBITDA | -$176.4M | -$210.5M | -$164.7M | -$45.3M | -$41.3M | |
| Diluted EPS | -$2.61 | -$1.57 | -$1.59 | -$0.08 | -$0.30 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $673M | $448.3M | $444.4M | $369M | $461M | |
| Total Assets | $741.7M | $550.9M | $583.8M | $505M | $516.5M | |
| Current Liabilities | $320.3M | $171.3M | $239.7M | $295.6M | $372.3M | |
| Total Liabilities | $611M | $648M | $717.4M | $593M | $428.7M | |
| Total Equity | $130.8M | -$97.1M | -$133.6M | -$88M | $87.8M | |
| Total Debt | $418.8M | $480.7M | $478.7M | $297.9M | $52.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$261.9M | -$62M | -$90.2M | -$62M | -$46.3M | |
| Cash From Investing | -$20.5M | $266.1M | $377.4M | $444K | -$67.2M | |
| Cash From Financing | $75.8M | -$186.8M | -$281.6M | -$167K | $2K | |
| Free Cash Flow | -$262.2M | -$62M | -$90.2M | -$62M | -$46.3M | |
CHRS
Sector
Market Cap
$162M
$27.9M
Price % of 52-Week High
70.9%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
25.38%
-1.55%
1-Year Price Total Return
-10.07%
-17.49%
Beta (5-Year)
0.951
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.36
200-day SMA
Buy
Level
$1.13
Bollinger Bands (100)
Sell
Level
1.14 - 1.62
Chaikin Money Flow
Buy
Level
137.6K
20-day SMA
Buy
Level
$1.32
Relative Strength Index (RSI14)
Sell
Level
49.83
ADX Line
Sell
Level
13.93
Williams %R
Neutral
Level
-60.5411
50-day SMA
Sell
Level
$1.41
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
6.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.6302)
Sell
CA Score
(Annual)
Level (-4.8176)
Buy
Beneish M-Score
(Annual)
Level (-2.6559)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (0.5278)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Stock Forecast FAQ
In the current month, CHRS has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CHRS average analyst price target in the past 3 months is $5.67.
-
Where Will Coherus Oncology, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Coherus Oncology, Inc. share price will rise to $5.67 per share over the next 12 months.
-
What Do Analysts Say About Coherus Oncology, Inc.?
Analysts are divided on their view about Coherus Oncology, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Coherus Oncology, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Coherus Oncology, Inc.'s Price Target?
The price target for Coherus Oncology, Inc. over the next 1-year time period is forecast to be $5.67 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CHRS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Coherus Oncology, Inc. is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CHRS?
You can purchase shares of Coherus Oncology, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Coherus Oncology, Inc. shares.
-
What Is The Coherus Oncology, Inc. Share Price Today?
Coherus Oncology, Inc. was last trading at $1.34 per share. This represents the most recent stock quote for Coherus Oncology, Inc.. Yesterday, Coherus Oncology, Inc. closed at $1.34 per share.
-
How To Buy Coherus Oncology, Inc. Stock Online?
In order to purchase Coherus Oncology, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CHRS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CHRS
Sector
P/E ratio
1.06x
23.75x
PEG ratio
-0.90x
-0.01x
P/B ratio
1.85x
1.81x
Price / LTM sales
1.86x
1.59x
Growth Metrics
CHRS
Sector
Revenue growth
91.19%
4.6%
Earnings growth
-260.07%
10.88%
Revenue (5-year growth)
-5.6%
6.45%
Earnings forecast
-$0.29
-$0.21
Profitability
CHRS
Sector
Profitability FY 2024
$144.1M
$3.6M
Return on invested capital
-115.69%
-31.84%
Return on assets
-40.99%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Feb
5
Balance Sheet
CHRS
Sector
Total cash
$191.7M
$26.3M
Short term investments
--
$25.7M
Total assets
$454.8M
$76.9M
Long term debt
$52.5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 36.69% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 1.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 4.26% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
